AR067823A1 - Compuestos de amina ciclica - Google Patents
Compuestos de amina ciclicaInfo
- Publication number
- AR067823A1 AR067823A1 ARP080103428A ARP080103428A AR067823A1 AR 067823 A1 AR067823 A1 AR 067823A1 AR P080103428 A ARP080103428 A AR P080103428A AR P080103428 A ARP080103428 A AR P080103428A AR 067823 A1 AR067823 A1 AR 067823A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- substituents
- optionally
- sulfur
- Prior art date
Links
- -1 CYCLINE AMINE COMPOUNDS Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto representado por la formula 1en donde R1 es un átomo de hidrogeno, un átomo dé halogeno, un grupo a través de un átomo de carbono, un grupo a través de un átomo de nitrogeno, un grupo a través de un átomo de oxigeno o un grupo a través de un átomo de azufre; R2 es un átomo de hidrogeno, un átomo de halogeno, un grupo a través de un átomo de carbono, un grupo a través de un átomo de nitrogeno, un grupo a través de un átomo de oxigeno o un grupo a través de un átomo de azufre; R3 es un grupo extractor de electrones; R4 es un átomo de hidrogeno, un átomo de halogeno, un grupo a través de un átomo de carbono, un grupo a través de un átomo de nitrogeno, un grupo a través de un átomo de oxigeno o un grupo a través de un átomo de azufre; R5 es un átomo de hidrogeno, un átomo de halogeno, un grupo a través de un átomo de carbono, un grupo a través de un átomo de nitrogeno, un grupo a través de un átomo de oxigeno o un grupo a través de un átomo de azufre; R6 es un átomo de hidrogeno, un átomo de halogeno, un grupo a través de un átomo de carbono, un grupo a través de un átomo de nitrogeno, un grupo a través de un átomo de oxigeno o un grupo a través de un átomo de azufre; R7 es un grupo alquilo que opcionalmente tiene sustituyentes o un grupo aralquilo que opcionalmente tiene sustituyentes; R8 es un átomo de hidrogeno, un grupo alquilo que opcionalmente tiene sustituyentes, un grupo alquenilo que opcionalmente tiene sustituyentes o un grupo cicloalquilo que opcionalmente tiene sustituyentes; R9 es un grupo a través de un átomo de oxigeno; y el Anillo A es un anillo de 5 o 6 miembros que también tiene opcionalmente sustituyentes (en este caso, el Anillo A puede ser un anillo de 5 o 6 miembros que forma un enlace espiro con cicloalcano C3-6) o una de sus sales tiene una accion moduladora del receptor de androgenos superior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007205966 | 2007-08-07 | ||
| JP2007299658 | 2007-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067823A1 true AR067823A1 (es) | 2009-10-21 |
Family
ID=40329363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103428A AR067823A1 (es) | 2007-08-07 | 2008-08-06 | Compuestos de amina ciclica |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US8420694B2 (es) |
| EP (1) | EP2176220B1 (es) |
| JP (1) | JP5292390B2 (es) |
| KR (1) | KR20100049644A (es) |
| CN (1) | CN101821235B (es) |
| AR (1) | AR067823A1 (es) |
| AU (1) | AU2008284662B2 (es) |
| BR (1) | BRPI0814957B8 (es) |
| CA (1) | CA2695852C (es) |
| CL (1) | CL2008002313A1 (es) |
| CO (1) | CO6160326A2 (es) |
| CR (1) | CR11266A (es) |
| CY (1) | CY1114067T1 (es) |
| DK (1) | DK2176220T3 (es) |
| DO (1) | DOP2010000053A (es) |
| EA (1) | EA017429B1 (es) |
| ES (1) | ES2406685T3 (es) |
| GE (1) | GEP20125571B (es) |
| HR (1) | HRP20130374T1 (es) |
| JO (1) | JO2864B1 (es) |
| MA (1) | MA31639B1 (es) |
| ME (1) | ME01579B (es) |
| MX (1) | MX2010001484A (es) |
| MY (1) | MY159910A (es) |
| NZ (1) | NZ583624A (es) |
| PE (1) | PE20090899A1 (es) |
| PL (1) | PL2176220T3 (es) |
| PT (1) | PT2176220E (es) |
| RS (1) | RS52812B (es) |
| SI (1) | SI2176220T1 (es) |
| TN (1) | TN2010000062A1 (es) |
| TW (1) | TWI418543B (es) |
| WO (1) | WO2009020234A2 (es) |
| ZA (1) | ZA201001289B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009020234A2 (en) * | 2007-08-07 | 2009-02-12 | Takeda Pharmaceutical Company Limited | Pyrrolidin-2 -one derivatives as androgen receptor modulator |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| US8067448B2 (en) | 2008-02-22 | 2011-11-29 | Radius Health, Inc. | Selective androgen receptor modulators |
| PE20091653A1 (es) * | 2008-03-26 | 2009-11-14 | Takeda Pharmaceutical | Derivados sustituidos de pirazol y su uso |
| WO2011097496A1 (en) | 2010-02-04 | 2011-08-11 | Radius Health, Inc. | Selective androgen receptor modulators |
| MX342898B (es) | 2010-05-12 | 2016-10-18 | Radius Health Inc * | Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol. |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| ES2550319T3 (es) * | 2010-09-28 | 2015-11-06 | Radius Health, Inc | Moduladores selectivos del receptor de andrógenos |
| WO2013152170A1 (en) * | 2012-04-04 | 2013-10-10 | Catylix, Inc. | Selective androgen receptor modulators |
| EP3378472A1 (en) | 2012-08-09 | 2018-09-26 | Dynamis Therapeutics, Inc. | Combinations of meglumine |
| KR102069008B1 (ko) | 2012-09-21 | 2020-02-11 | 메르크 파텐트 게엠베하 | C-c 삼중 결합을 갖는 화합물 및 액정 혼합물에서 이의 용도 |
| SI3122426T1 (sl) | 2014-03-28 | 2023-04-28 | Duke University | Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| KR101597327B1 (ko) * | 2014-04-24 | 2016-02-24 | 동아에스티 주식회사 | 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제 |
| CN103951688B (zh) * | 2014-05-06 | 2016-04-20 | 成都安斯利生物医药有限公司 | 一种制备3,5-二氟-4-甲基苯硼酸的方法 |
| CA3027563C (en) | 2016-06-22 | 2024-07-02 | Ellipses Pharma Ltd | AR+ METHODS FOR BREAST CANCER TREATMENT |
| ES2981967T3 (es) | 2017-01-05 | 2024-10-14 | Radius Pharmaceuticals Inc | Formas polimórficas de RAD1901-2HCl |
| WO2020010216A1 (en) | 2018-07-04 | 2020-01-09 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad 1901-2hcl |
| PE20211733A1 (es) | 2019-01-11 | 2021-09-06 | Gruenenthal Chemie | Amidas de pirrolidina sustituidas |
| PH12021551950A1 (en) | 2019-02-12 | 2022-05-23 | Radius Pharmaceuticals Inc | Processes and compounds |
| CN110204505B (zh) * | 2019-05-31 | 2023-02-03 | 荆门医药工业技术研究院 | (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺 |
| US20230012570A1 (en) * | 2019-11-20 | 2023-01-19 | Medshine Discovery Inc. | Bicyclic compound used as selective androgen receptor modulator |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4141399A1 (de) | 1991-12-16 | 1993-06-17 | Bayer Ag | 4-(substituierte)amino-3-arylpyrrolinon-derivate |
| JP3390744B2 (ja) * | 1998-09-22 | 2003-03-31 | 山之内製薬株式会社 | シアノフェニル誘導体 |
| US6258833B1 (en) | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US7026500B2 (en) | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
| FR2817472B1 (fr) | 2000-12-06 | 2003-01-03 | Oreal | Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre |
| HRP20040588A2 (en) | 2001-12-06 | 2004-10-31 | Gtx Inc | Treating muscle wasting with selective androgen receptor modulators |
| JP4316232B2 (ja) | 2001-12-28 | 2009-08-19 | 武田薬品工業株式会社 | アンドロゲン受容体拮抗剤 |
| WO2003057669A1 (fr) * | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Antagonistes du recepteur androgene |
| CN100537520C (zh) | 2002-06-17 | 2009-09-09 | 田纳西大学研究基金会 | N-桥连选择性雄激素受体调节剂及其使用方法 |
| NZ538713A (en) * | 2002-08-12 | 2007-01-26 | Takeda Chemical Industries Ltd | Fused benzene derivative and use |
| GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| EP1747193A1 (en) * | 2004-05-11 | 2007-01-31 | Pfizer Products Incorporated | Benzonitrile derivatives to treat musculoskeletal frailty |
| ZA200610270B (en) | 2004-05-17 | 2008-06-25 | Acadia Pharm Inc | Androgen receptor modulators and method of treating disease using the same |
| ATE552235T1 (de) | 2004-06-07 | 2012-04-15 | Univ Tennessee Res Foundation | Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür |
| EP1836202B1 (en) | 2005-01-10 | 2016-12-21 | Acadia Pharmaceuticals Inc. | Aminophenyl derivatives as selective androgen receptor modulators |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| US7807691B2 (en) | 2005-05-13 | 2010-10-05 | Eli Lilly And Company | Substituted N-arylpyrrolidines as selective androgen receptor modulators |
| JP5070054B2 (ja) | 2005-08-01 | 2012-11-07 | 武田薬品工業株式会社 | 環状アミン化合物 |
| US20090042857A1 (en) * | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| MX2009000715A (es) * | 2006-07-19 | 2009-07-22 | Osurf Ohio State University Re | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. |
| RU2009106214A (ru) * | 2006-07-26 | 2010-09-10 | Новартис АГ (CH) | Ингибиторы ундекапренилпирофосфатсинтазы |
| JP5241507B2 (ja) | 2006-11-30 | 2013-07-17 | 武田薬品工業株式会社 | 環状アミン化合物 |
| WO2009020234A2 (en) * | 2007-08-07 | 2009-02-12 | Takeda Pharmaceutical Company Limited | Pyrrolidin-2 -one derivatives as androgen receptor modulator |
-
2008
- 2008-08-06 WO PCT/JP2008/064500 patent/WO2009020234A2/en not_active Ceased
- 2008-08-06 RS RS20130235A patent/RS52812B/sr unknown
- 2008-08-06 ES ES08792430T patent/ES2406685T3/es active Active
- 2008-08-06 CN CN2008801105925A patent/CN101821235B/zh not_active Expired - Fee Related
- 2008-08-06 PT PT87924304T patent/PT2176220E/pt unknown
- 2008-08-06 DK DK08792430.4T patent/DK2176220T3/da active
- 2008-08-06 KR KR1020107005062A patent/KR20100049644A/ko not_active Abandoned
- 2008-08-06 CL CL2008002313A patent/CL2008002313A1/es unknown
- 2008-08-06 PL PL08792430T patent/PL2176220T3/pl unknown
- 2008-08-06 MY MYPI2010000564A patent/MY159910A/en unknown
- 2008-08-06 JP JP2010504096A patent/JP5292390B2/ja not_active Expired - Fee Related
- 2008-08-06 AU AU2008284662A patent/AU2008284662B2/en not_active Ceased
- 2008-08-06 HR HRP20130374AT patent/HRP20130374T1/hr unknown
- 2008-08-06 TW TW097129774A patent/TWI418543B/zh not_active IP Right Cessation
- 2008-08-06 MX MX2010001484A patent/MX2010001484A/es active IP Right Grant
- 2008-08-06 PE PE2008001314A patent/PE20090899A1/es not_active Application Discontinuation
- 2008-08-06 BR BRPI0814957A patent/BRPI0814957B8/pt not_active IP Right Cessation
- 2008-08-06 US US12/672,516 patent/US8420694B2/en not_active Expired - Fee Related
- 2008-08-06 GE GEAP200811715A patent/GEP20125571B/en unknown
- 2008-08-06 EP EP08792430A patent/EP2176220B1/en active Active
- 2008-08-06 CA CA2695852A patent/CA2695852C/en active Active
- 2008-08-06 US US12/221,739 patent/US7834051B2/en active Active
- 2008-08-06 SI SI200830941T patent/SI2176220T1/sl unknown
- 2008-08-06 NZ NZ583624A patent/NZ583624A/en not_active IP Right Cessation
- 2008-08-06 EA EA201070246A patent/EA017429B1/ru unknown
- 2008-08-06 ME MEP-2013-64A patent/ME01579B/me unknown
- 2008-08-06 AR ARP080103428A patent/AR067823A1/es unknown
- 2008-08-09 JO JO2008353A patent/JO2864B1/en active
-
2010
- 2010-02-05 DO DO2010000053A patent/DOP2010000053A/es unknown
- 2010-02-05 TN TNP2010000062A patent/TN2010000062A1/fr unknown
- 2010-02-12 CR CR11266A patent/CR11266A/es unknown
- 2010-02-23 ZA ZA2010/01289A patent/ZA201001289B/en unknown
- 2010-02-26 MA MA32657A patent/MA31639B1/fr unknown
- 2010-03-05 CO CO10026475A patent/CO6160326A2/es unknown
-
2013
- 2013-06-21 CY CY20131100507T patent/CY1114067T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067823A1 (es) | Compuestos de amina ciclica | |
| DOP2010000068A (es) | Derivados de pirazol sustituidos | |
| AR066210A1 (es) | Proceso para producir compuesto amida | |
| ES2506169T3 (es) | Derivados de 5-fluoro-2-oxopirimidina-1(2H)-carboxilato como fungicidas | |
| MX343611B (es) | Composicion de control de fitoenfermedades y su uso. | |
| PE20221083A1 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso | |
| ECSP11010912A (es) | Compuestos de pirrol | |
| AR054130A1 (es) | Procedimiento para la preparacion de 1-alquil-3-feniluracilos | |
| MX2019006696A (es) | Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5. | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| CO6210751A2 (es) | Derivados de indolinona y procedimiento para su fabricacion | |
| AR067691A1 (es) | Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas. | |
| PE20211313A1 (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos | |
| ES2578628T3 (es) | Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4 | |
| AR078606A1 (es) | Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central | |
| AR077176A1 (es) | Derivado de piridina que contiene un anillo ((fosfonooxi) metil) piridinio y agente antifungico que contiene este derivado | |
| MX2018011721A (es) | Compuesto de griseofulvina. | |
| CY1121626T1 (el) | Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου | |
| PE20170245A1 (es) | Pirazinas moduladoras de gpr 6 | |
| AR064306A1 (es) | Antagonistas del receptor de angiotensina ii | |
| CO2018003909A2 (es) | Compuestos terapéuticos y sus métodos de uso | |
| CO5700747A2 (es) | Piperidinas novedosas como moduladores de quimoquina (ccr) | |
| MX370389B (es) | Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona. | |
| BR112019001015A2 (pt) | composto de benzilamida, método para produção do mesmo, e miticida | |
| DOP2011000296A (es) | Compuesto de pirazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |